Please login to the form below

Not currently logged in
Email:
Password:

Wales backs NHS use of Abraxane despite NICE rejection

Overrules UK decision and will maintain access to Celgene’s pancreatic cancer drug
Celgene

The Welsh government has over-ruled a decision by NICE not to recommend Celgene's pancreatic cancer drug for routine use by the NHS.

Abraxane (nab-paclitaxel) will now continue to be available to patients in Wales, even though NICE decided last November that the drug should not be funded as a combination therapy with gemcitabine for previously-untreated metastatic pancreatic cancer.

The cost-effectiveness watchdog said at the time that the drug's benefits did not justify its cost and also that it carried a side-effect burden that impacted patients' quality of life.

The All Wales Medicines Strategy Group (AWMSG) approved Abraxane as a first-line therapy in these patients, even though NICE's rulings generally take precedence in Wales.

Abraxane has been available on an interim basis in Wales since September 2014, when the drug was first backed by the AWMSG, several months after it gained EU approval as a first-line therapy. The Scottish Medicines Consortium (SMC) initially rejected the drug in June 2014, arguing it was too expensive, but has since changed its decision.

In a statement, the Welsh government said: "In light of the clear clinical need and the potential for the drug to have a positive impact on a patient population of between 400 and 500 people in Wales, the Welsh government has reached an agreement with … Celgene to secure continued access."

It added that the pharma company is planning to submit new real-world data to NICE that it hopes will sway the agency and has committed to a re-appraisal of the product within the next two years.

Abraxane was among those drugs de-listed from the Cancer Drugs Fund (CDF) in its cull last September, closing that route of access for patients wanting to start therapy with the drug.

Responding to the news, Pancreatic Cancer UK's chief executive Alex Ford said that the situation has left a "divided UK where eligible patients in Wales and Scotland can access the treatment, whilst those living in England and Northern Ireland cannot."

"Such unfairness will anger and confuse many patients and families who we support," she added.

Celgene is now planning to make a re-submission to NICE with more data to support its use across the UK, and Pancreatic Cancer UK is urging "all parties to get around the table and make this happen as soon as possible".

Article by
Phil Taylor

21st March 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

14_ipad_lowres.jpg
Do your customers feel that you’re listening to them?
When answering to data, excellent digital communication can create much stronger relationships between reps and customers....
Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...

Infographics